156 related articles for article (PubMed ID: 17426207)
41. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.
Zeiger RS; Bird SR; Kaplan MS; Schatz M; Pearlman DS; Orav EJ; Hustad CM; Edelman JM
Am J Med; 2005 Jun; 118(6):649-57. PubMed ID: 15922697
[TBL] [Abstract][Full Text] [Related]
42. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study.
Garcia Garcia ML; Wahn U; Gilles L; Swern A; Tozzi CA; Polos P
Pediatrics; 2005 Aug; 116(2):360-9. PubMed ID: 16061590
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
[TBL] [Abstract][Full Text] [Related]
44. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
Currie GP; Lee DK; Haggart K; Bates CE; Lipworth BJ
Am J Respir Crit Care Med; 2003 May; 167(9):1232-8. PubMed ID: 12456382
[TBL] [Abstract][Full Text] [Related]
45. Role of nitric oxide on airway microvascular permeability in patients with asthma.
Tohyama Y; Kanazawa H; Fujiwara H; Hirata K; Fujimoto S; Yoshikawa J
Osaka City Med J; 2005 Jun; 51(1):1-9. PubMed ID: 16334611
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats.
Melgar-Lesmes P; Tugues S; Ros J; Fernández-Varo G; Morales-Ruiz M; Rodés J; Jiménez W
Gut; 2009 Feb; 58(2):285-92. PubMed ID: 18978178
[TBL] [Abstract][Full Text] [Related]
47. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.
Wang K; Liu CT; Wu YH; Feng YL; Bai HL
Adv Ther; 2008 Apr; 25(4):342-54. PubMed ID: 18421428
[TBL] [Abstract][Full Text] [Related]
48. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial.
Rand C; Bilderback A; Schiller K; Edelman JM; Hustad CM; Zeiger RS;
J Allergy Clin Immunol; 2007 Apr; 119(4):916-23. PubMed ID: 17349681
[TBL] [Abstract][Full Text] [Related]
49. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.
Ostrom NK; Decotiis BA; Lincourt WR; Edwards LD; Hanson KM; Carranza Rosenzweig JR; Crim C
J Pediatr; 2005 Aug; 147(2):213-20. PubMed ID: 16126052
[TBL] [Abstract][Full Text] [Related]
50. Effects of inhaled fluticasone propionate on CTLA-4-positive CD4+CD25+ cells in induced sputum in mild asthmatics.
Kawayama T; Kinoshita T; Imaoka H; Gauvreau GM; O'Byrne PM; Aizawa H
Respirology; 2008 Nov; 13(7):1000-1007. PubMed ID: 18699801
[TBL] [Abstract][Full Text] [Related]
51. Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma.
Mendes ES; Campos MA; Hurtado A; Wanner A
Am J Respir Crit Care Med; 2004 May; 169(10):1131-4. PubMed ID: 15028562
[TBL] [Abstract][Full Text] [Related]
52. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Pearlman DS; White MV; Lieberman AK; Pepsin PJ; Kalberg C; Emmett A; Bowers B; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):227-35. PubMed ID: 11868930
[TBL] [Abstract][Full Text] [Related]
53. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation.
O'Sullivan S; Akveld M; Burke CM; Poulter LW
Am J Respir Crit Care Med; 2003 Mar; 167(5):745-50. PubMed ID: 12480610
[TBL] [Abstract][Full Text] [Related]
54. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients.
van der Heijden M; van Nieuw Amerongen GP; Koolwijk P; van Hinsbergh VW; Groeneveld AB
Thorax; 2008 Oct; 63(10):903-9. PubMed ID: 18559364
[TBL] [Abstract][Full Text] [Related]
55. Asthma-related health care resource use among patients starting fluticasone or montelukast therapy.
Allen-Ramey FC; Anstatt DT; Sajjan SG; Markson LE
Pharmacotherapy; 2005 Dec; 25(12):1752-60. PubMed ID: 16305295
[TBL] [Abstract][Full Text] [Related]
56. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening AP; Haahtela T; Holgate ST; Picado C; Menten J; Dass SB; Leff JA; Polos PG
BMJ; 2003 Oct; 327(7420):891. PubMed ID: 14563743
[TBL] [Abstract][Full Text] [Related]
57. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma.
Kanazawa H; Asai K; Hirata K; Yoshikawa J
Chest; 2002 Jul; 122(1):166-70. PubMed ID: 12114353
[TBL] [Abstract][Full Text] [Related]
58. Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms.
Balantic M; Rijavec M; Skerbinjek Kavalar M; Suskovic S; Silar M; Kosnik M; Korosec P
Mol Diagn Ther; 2012 Jun; 16(3):173-80. PubMed ID: 22519966
[TBL] [Abstract][Full Text] [Related]
59. The interaction of soluble Tie2 with angiopoietins and pulmonary vascular permeability in septic and nonseptic critically ill patients.
van der Heijden M; van Nieuw Amerongen GP; van Hinsbergh VW; Groeneveld AB
Shock; 2010 Mar; 33(3):263-8. PubMed ID: 19543148
[TBL] [Abstract][Full Text] [Related]
60. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
